A closer look at Bristol-Myers Squibbs voluntary ARV licenses
-------------------------------------------------------------
Dear colleagues
You may have heard that Bristol-Myers Squibb (BMS) has granted a
license to one of India's large generic manufacturers, Aurobindo
Pharma, to produce and market the antiretrovirals (ARVs) sta-
vudine and didanosine in 49 countries including South Africa
(which may be the only African country in which BMS has sought
patents). While any effort from the industry towards increasing
access to ARVs is welcome, it is always interesting to investi-
gate the details of such endeavours. In doing so, HAI Africa
wishes to highlight the fact that BMS's recent licensing gesture
is not as surprising or generous as it might first appear.
Read the full story on the HAI Africa web site:
http://www.haiafrica.org
Best regards,
Elizabeth Betty Amailuk
Network and Communications Manager
Health Action International (HAI)
Africa Bush House, opposite Polish Embassy
Kabarnet Lane off Ngong Road
P.O. Box 66054 00800 Nairobi, Kenya
Tel: +254-20-3860-434-6
Fax: +254-20-3860-437
mailto:betty@haiafrica.org
http://www.haiafrica.org